LESLIE STELLY: Open Payments
NPI 1205448651 · WELSH, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$507 in 24 payments from 10 companies in 2025. Trend: 2023 $440 · 2024 $270 · 2025 $507
Food & beverage: $507
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $160 |
| Lilly USA, LLC | 6 | $118 |
| Axsome Therapeutics, Inc. | 4 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
Products named: JARDIANCE, FARXIGA, Auvelity, CAPLYTA, BREZTRI, TRINTELLIX, Qelbree, VRAYLAR.
Industry payments across LA — which companies pay providers there.
